What is Recombinant Human Growth Hormone Market?
Human growth hormone is a peptide pituitary hormone of about 190 amino acids that stimulates growth, cell reproduction, and regeneration. This hormone is synthesized and secreted by cells called somatotrophs in the anterior pituitary and also regulates body composition, fluids, and sugar and fat metabolism. Human growth hormone can be used to treat growth disorders and growth hormone deficiency. Recombinant human growth hormones are made in a laboratory using recombinant technology. These hormones work by stimulating growth in the body and used to treat growth hormone deficiency and to aid in weight gain. In the past years, recombinant human growth hormone (rhGH) primarily used for stimulating the growth of growth-retarded GH deficient (GHD) children. Recently it is being used for other conditions associated with short stature, including Turner syndrome and end-stage renal disease.
The market study is being classified, by Application (Growth Hormone (GH) Deficiency, Adult GH Deficiency, Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age and Other) and major geographies with country level break-up.
Pfizer, Inc (United States), Novo Nordisk A/S (Denmark), Eli Lilly and Company (United States), Sandoz International GmbH (Germany), Merck Group (Germany), Genentech, Inc. (United States), Ferring Pharmaceuticals (Switzerland), Teva Pharmaceutical Industries, Ltd (Israel), Ipsen (France) and AnkeBio Co. Ltd (China) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Recombinant Human Growth Hormone market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Recombinant Human Growth Hormone market by Type, Application and Region.
On the basis of geography, the market of Recombinant Human Growth Hormone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Hormone Deficiency in Children
- Rise in the Off-label Usage of Growth Hormone
- Technological Advancements in the Medical Science
- Side Effects of the Recombinant Human Growth Hormone
- Increased Research and Development Investment
- Huge Investments by Major Players
- Stringent Government Rules and Regulations
Market Leaders and some development strategies
In December 2020, Emisphere Technologies, Inc., a drug delivery company that utilizes its proprietary technologies to develop new oral formulations of therapeutic agents, has announced the completion of the previously announced transaction whereby Novo Nordisk A/S acquired Emisphere, on a cash-free, debt-free basis.
Key Target AudienceRecombinant Human Growth Hormone Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase